Preliminary report of intraovarian injections of autologous platelet-rich plasma (PRP) in extremely poor prognosis patients with only oocyte donation as alternative: a prospective cohort study

D H Barad, D F Albertini, E Molinari, N Gleicher, D H Barad, D F Albertini, E Molinari, N Gleicher

Abstract

Study question: Does intraovarian injection of platelet-rich plasma (PRP) change ovarian function in patients with extremely low functional ovarian reserve (LFOR) who, otherwise, would likely only have a chance of pregnancy through third-party oocyte donation?

Summary answer: No clinically significant effects of PRP treatment on ovarian function were observed over 1 year of follow-up.

What is known already: Several investigators have reported improved responses to ovulation induction after treatment with PRP. However, previous published reports have involved, at most, only small case series. Whether PRP actually improves ovarian performance is, therefore, still unknown. PRP is nevertheless widely offered as an 'established' fertility treatment, often under the term 'ovarian rejuvenation'.

Study design size duration: We are reporting a prospective cohort study of 80 consecutive patients at ages 28-54 with LFOR, defined by anti-Müllerian hormone <1.1 ng/ml, FSH >12 mIU/ml or at least one prior IVF cycle with ≤3 oocytes within 1 year. The women were followed for 1 year after an intraovarian PRP procedure.

Participants/materials setting methods: PRP (1.5 ml) was injected into the cortex of ovaries with an average of 12 injections per ovary. Study participants were followed every 3 days for 2 weeks after PRP treatment with estradiol and FSH measurements and vaginal ultrasound to observe follicle growth and thereafter followed weekly. Beginning 1 month after their PRP treatment, participants underwent one or more cycles of ovarian stimulation for IVF. Outcome measures were endocrine response, and numbers of oocytes and embryos produced in response to a maximal gonadotropin stimulation before and after PRP treatment.

Main results and the role of chance: In this study, women failed to demonstrate statistically significant outcome benefits from intraovarian PRP. However, two 40-year-old very poor-prognosis patients, with prior failed IVF cycles that never reached embryo transfer at other centers, achieved pregnancy, resulting in an ongoing pregnancy rate of 4.7% among patients who, following PRP, produced at least one oocyte (n = 42).

Limitations reasons for caution: As an observational study of patients who performed poorly in past ovarian stimulation cycles, the improvement may be accounted for by regression to the mean. Similar considerations may also explain the occurrence of the two pregnancies.

Wider implications of the findings: This study demonstrates that, even in extremely poor prognosis patients due to LFOR, sporadic pregnancies are possible. The study, however, does not allow for the conclusion that those pregnancies were the consequence of PRP treatments. A case series, indeed, does not allow for such conclusions, even if results are more suggestive than here. This registered study, therefore, must be viewed as a preliminary report, with further data expected from this study but also from two other prospectively randomized ongoing registered studies with more controlled patient selection.

Study funding/competing interests: This work was supported by intramural funds from The Center for Human Reproduction and the not-for-profit research Foundation for Reproductive Medicine, both in New York, NY, USA. N.G. and D.H.B. are listed as co-inventors on several US patents. Some of these patents relate to pre-supplementation of hypo-androgenic infertile women with androgens, such as dehydroepiandrosterone and testosterone and, therefore, at least peripherally relate to the subject of this manuscript. They, as well as D.F.A., have also received research support, travel funds and speaker honoraria from several pharmaceutical and medical device companies, though none related to the here presented subject and manuscript. N.G. is a shareholder in Fertility Nutraceuticals and he and D.H.B. receive royalty payments from Fertility Nutraceuticals LLC. E.M. has no conflicts of interest to declare.

Trial registration number: NCT04275700.

Keywords: IVF; functional ovarian reserve (FOR); ovarian insufficiency; ovarian reserve; platelet-rich plasma (PRP).

© The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology.

References

    1. Alviggi C, Andersen CY, Buehler K, Conforti A, De Placido G, Esteves SC, Fischer R, Galliano D, Polyzos NP, Sunkara SK. et al.; Poseidon Group (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number). A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril 2016;105:1452–1453.
    1. Atkinson L, Martin F, Sturmey RG.. Intraovarian injection of platelet-rich plasma in assisted reproduction: too much too soon? Hum Reprod 2021;36:1737–1750.
    1. Barad D, Brill H, Gleicher N.. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J Assist Reprod Genet 2007;24:629–634.
    1. Barad D, Gleicher N.. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum Reprod 2006;21:2845–2849.
    1. Barad DH, Gleicher N.. Increased oocyte production after treatment with dehydroepiandrosterone. Fertil Steril 2005;84:756.
    1. Cai YF, Tian TZ, Chen LY, Liu BX, Zhou JP, Shi M, Liang HD.. The effect of platelet-rich plasma on the fusion rate and clinical outcome of spinal fusion surgery: a systematic review and meta-analysis. PLoS One 2020;15:e0243204.
    1. Cakiroglu Y, Saltik A, Yuceturk A, Karaosmanoglu O, Kopuk SY, Scott RT, Tiras B, Seli E.. Effects of intraovarian injection of autologous platelet rich plasma on ovarian reserve and IVF outcome parameters in women with primary ovarian insufficiency. Aging (Albany NY) 2020;12:10211–10222.
    1. Casson PR, Lindsay MS, Pisarska MD, Carson SA, Buster JE.. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Hum Reprod 2000;15:2129–2132.
    1. Dakhly DMR, Bassiouny YA, Bayoumi YA, Hassan MA, Gouda HM, Hassan AA.. The addition of growth hormone adjuvant therapy to the long down regulation protocol in poor responders undergoing in vitro fertilization: randomized control trial. Eur J Obstet Gynecol Reprod Biol 2018;228:161–165.
    1. Dhurat R, Sukesh M.. Principles and methods of preparation of platelet-rich plasma: a review and author's perspective. J Cutan Aesthet Surg 2014;7:189–197.
    1. Esteves SC, Alviggi C, Humaidan P, Fischer R, Andersen CY, Conforti A, Bühler K, Sunkara SK, Polyzos NP, Galliano D. et al. The POSEIDON criteria and its measure of success through the eyes of clinicians and embryologists. Front Endocrinol (Lausanne) 2019;10:814.
    1. Fabi S, Sundaram H.. The potential of topical and injectable growth factors and cytokines for skin rejuvenation. Facial Plast Surg 2014;30:157–171.
    1. Farimani M, Heshmati S, Poorolajal J, Bahmanzadeh M.. A report on three live births in women with poor ovarian response following intra-ovarian injection of platelet-rich plasma (PRP). Mol Biol Rep 2019;46:1611–1616.
    1. Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L, Definition E; ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod 2011;26:1616–1624.
    1. Findlay JK, Dunning KR, Gilchrist RB, Hutt KJ, Russell DL, Walters KA.. Chapter 1—follicle selection in mammalian ovaries. In: Leung PCK, Adashi EY (eds). The Ovary, 3rd edn. London: Academic Press, 2019, 3–21.
    1. Gentile P, Garcovich S.. Autologous activated platelet-rich plasma (AA-PRP) and non-activated (A-PRP) in hair growth: a retrospective, blinded, randomized evaluation in androgenetic alopecia. Expert Opin Biol Ther 2020;20:327–337.
    1. Gleicher N, Kim A, Weghofer A, Kushnir VA, Shohat-Tal A, Lazzaroni E, Lee HJ, Barad DH.. Hypoandrogenism in association with diminished functional ovarian reserve. Hum Reprod 2013;28:1084–1091.
    1. Gleicher N, Kushnir VA, Darmon S, Albertini DF, Barad DH.. Older women using their own eggs? Issue framed with two oldest reported IVF pregnancies and a live birth. Reprod Biomed Online 2018;37:172–177.
    1. Gleicher N, Weghofer A, Barad DH.. Defining ovarian reserve to better understand ovarian aging. Reprod Biol Endocrinol 2011;9:23.
    1. Guida A, Cecoro G, Rullo R, Laino L, Del Fabbro M, Annunziata M.. A systematic critical appraisal of the methodological quality of systematic reviews on the effect of autologous platelet concentrates in the treatment of periodontal intraosseous defects. Materials (Basel, Switzerland) 2020;13:4180.
    1. Haydardedeoglu B, Isik AZ, Bulgan Kilicdag E.. The combination of dehydroepiandrosterone, transdermal testosterone, and growth hormone as an adjuvant therapy in assisted reproductive technology cycles in patients aged below 40 years with diminished ovarian reserve. Turk J Obstet Gynecol 2015;12:60–65.
    1. Homburg R, Singh A, Bhide P, Shah A, Gudi A.. The re-growth of growth hormone in fertility treatment: a critical review. Hum Fertil (Camb) 2012;15:190–193.
    1. Hosseini L, Shirazi A, Naderi MM, Shams-Esfandabadi N, Borjian Boroujeni S, Sarvari A, Sadeghnia S, Behzadi B, Akhondi MM.. Platelet-rich plasma promotes the development of isolated human primordial and primary follicles to the preantral stage. Reprod Biomed Online 2017;35:343–350.
    1. Hsueh AJW, Kawamura K.. Hippo signaling disruption and ovarian follicle activation in infertile patients. Fertil Steril 2020;114:458–464.
    1. Lippross S, Moeller B, Haas H, Tohidnezhad M, Steubesand N, Wruck CJ, Kurz B, Seekamp A, Pufe T, Varoga D.. Intraarticular injection of platelet-rich plasma reduces inflammation in a pig model of rheumatoid arthritis of the knee joint. Arthritis Rheum 2011;63:3344–3353.
    1. Macaulay IC, Carr P, Gusnanto A, Ouwehand WH, Fitzgerald D, Watkins NA.. Platelet genomics and proteomics in human health and disease. J Clin Invest 2005;115:3370–3377.
    1. McRedmond JP, Park SD, Reilly DF, Coppinger JA, Maguire PB, Shields DC, Fitzgerald DJ.. Integration of proteomics and genomics in platelets: a profile of platelet proteins and platelet-specific genes. Mol Cell Proteomics 2004;3:133–144.
    1. Melo P, Navarro C, Jones C, Coward K, Coleman L.. The use of autologous platelet-rich plasma (PRP) versus no intervention in women with low ovarian reserve undergoing fertility treatment: a non-randomized interventional study. J Assist Reprod Genet 2020;37:855–863.
    1. Ouni E, Bouzin C, Dolmans MM, Marbaix E, Pyr Dit Ruys S, Vertommen D, Amorim CA.. Spatiotemporal changes in mechanical matrisome components of the human ovary from prepuberty to menopause. Hum Reprod 2020;35:1391–1410.
    1. Pantos K, Nitsos N, Kokkali G, Vaxevanoglou T, Markomichali C, Pantou A, Grammatis M, Lazaros L, Sfakianoudis K.. Ovarian rejuvenation and folliculogenesis reactivation in peri-menopausal women after autologous platelet-rich plasma treatment. Abstracts of the 32nd Annual Meeting of the European Society of Human Reproduction and Embryology, Hum Reprod 2016;31, Issue suppl_1:i301.
    1. Pantos K, Simopoulou M, Pantou A, Rapani A, Tsioulou P, Nitsos N, Syrkos S, Pappas A, Koutsilieris M, Sfakianoudis K.. A case series on natural conceptions resulting in ongoing pregnancies in menopausal and prematurely menopausal women following platelet-rich plasma treatment. Cell Transplant 2019;28:1333–1340.
    1. Peerbooms JC, Sluimer J, Bruijn DJ, Gosens T.. Positive effect of an autologous platelet concentrate in lateral epicondylitis in a double-blind randomized controlled trial: platelet-rich plasma versus corticosteroid injection with a 1-year follow-up. Am J Sports Med 2010;38:255–262.
    1. Raeissadat SA, Rayegani SM, Hassanabadi H, Fathi M, Ghorbani E, Babaee M, Azma K.. Knee osteoarthritis injection choices: platelet-rich plasma (PRP) versus hyaluronic acid (a one-year randomized clinical trial). Clin Med Insights Arthritis Musculoskelet Disord 2015;8:1–8.
    1. Rinaudo P, Albertini D.. Will PRP therapy find a niche in reproductive medicine? Not ready for prime time. J Assist Reprod Genet 2021;38:1013–1014.
    1. Sánchez-González DJ, Méndez-Bolaina E, Trejo-Bahena NI.. Platelet-rich plasma peptides: key for regeneration. Int J Pept 2012;2012:532519.
    1. Sellix MT, Sen A.. Finding the right balance: androgens at the tipping point of fertility and metabolism in women. Endocrinology 2017;158:467–469.
    1. Sfakianoudis K, Simopoulou M, Nitsos N, Rapani A, Pantou A, Vaxevanoglou T, Kokkali G, Koutsilieris M, Pantos K.. A case series on platelet-rich plasma revolutionary management of poor responder patients. Gynecol Obstet Invest 2019;84:99–106.
    1. Sharara FI, Lelea LL, Rahman S, Klebanoff JS, Moawad GN.. A narrative review of platelet-rich plasma (PRP) in reproductive medicine. J Assist Reprod Genet 2021;38:1003–1012.
    1. Sills ES. The scientific and cultural journey to ovarian rejuvenation: background, barriers, and beyond the biological clock. Medicines (Basel) 2021;8:29.
    1. Sills ES, Rickers NS, Li X, Palermo GD.. First data on in vitro fertilization and blastocyst formation after intraovarian injection of calcium gluconate-activated autologous platelet rich plasma. Gynecol Endocrinol 2018;34:756–760.
    1. Sills ES, Rickers NS, Petersen JL, Li X, Wood SH.. Regenerative effect of intraovarian injection of activated autologous platelet rich plasma: serum anti-mullerian hormone levels measured among poor prognosis IVF patients. Int J Reg Med 2020;3:1–5.
    1. Sills ES, Wood SH.. Autologous activated platelet-rich plasma injection into adult human ovary tissue: molecular mechanism, analysis, and discussion of reproductive response. Biosci Rep 2019;39:BSR20190805.
    1. Thanasas C, Papadimitriou G, Charalambidis C, Paraskevopoulos I, Papanikolaou A.. Platelet-rich plasma versus autologous whole blood for the treatment of chronic lateral elbow epicondylitis: a randomized controlled clinical trial. Am J Sports Med 2011;39:2130–2134.
    1. Tong S, Zhang C, Liu J.. Platelet-rich plasma exhibits beneficial effects for rheumatoid arthritis mice by suppressing inflammatory factors. Mol Med Rep 2017;16:4082–4088.
    1. Watson SP, Bahou WF, Fitzgerald D, Ouwehand W, Rao AK, Leavitt AD.. ISTH platelet physiology subcommittee: mapping the platelet proteome: a report of the ISTH platelet physiology subcommittee. J Thromb Haemost 2005;3:2098–2101.
    1. Wolf JM, Ozer K, Scott F, Gordon MJ, Williams AE.. Comparison of autologous blood, corticosteroid, and saline injection in the treatment of lateral epicondylitis: a prospective, randomized, controlled multicenter study. J Hand Surg Am 2011;36:1269–1272.
    1. Wu YG, Barad DH, Kushnir VA, Lazzaroni E, Wang Q, Albertini DF, Gleicher N.. Aging-related premature luteinization of granulosa cells is avoided by early oocyte retrieval. J Endocrinol 2015;226:167–180.
    1. Wu YG, Barad DH, Kushnir VA, Wang Q, Zhang L, Darmon SK, Albertini DF, Gleicher N.. With low ovarian reserve, highly individualized egg retrieval (HIER) improves IVF results by avoiding premature luteinization. J Ovarian Res 2018;11:23.
    1. Xie X, Zhang C, Tuan RS.. Biology of platelet-rich plasma and its clinical application in cartilage repair. Arthritis Res Ther 2014;16:204.
    1. Yao D, Feng G, Zhao F, Hao D.. Effects of platelet-rich plasma on the healing of sternal wounds: a meta-analysis. Wound Repair Regen 2021;29:153–167.
    1. Zhao K, Liu YS, Nie LY, Qian LN, Nie NF, Leptihn S, Bunpetch V, Xu JQ, Zou XH, Ouyang H.. The influence of sample size and gender composition on the meta-analysis conclusion of platelet-rich plasma treatment for osteoarthritis. J Orthop Translat 2020;22:34–42.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren